A carregar...
CXCR4 Based Therapeutics for Non-Small Cell Lung Cancer (NSCLC)
Lung cancer is the second most common malignancy. Unfortunately, despite advances in multimodality therapeutics for the disease, the overall five-year survival rate among newly diagnosed lung cancer patients remains in the range region of 15%. In addition, although immune checkpoint inhibitors are i...
Na minha lista:
| Publicado no: | J Clin Med |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6210654/ https://ncbi.nlm.nih.gov/pubmed/30257500 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm7100303 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|